Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland: REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ -- Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today...

Click to view original post